Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal reported Q2 2026 revenue of $364.3 million, up 71% year-over-year, driven by strong demand for Rezdiffra which now has over 49,000 patients on therapy, more than doubling from the prior year. The company advanced its pipeline by initiating Phase 1 dosing for MGL-2086, an oral GLP-1 intended for combination therapy, and secured new patents extending resmetirom protection into the 2040s.
Key figures
- Revenue
- 364300000
- Revenue Yoy
- 71%
- Net loss
- $57.9 million
- Rd expenses
- $91.2 million
- Sga expenses
- $289.4 million
- Cash position
- $838.9 million
- Patient count
- >49,000
- Operating expenses
- $420.6 million
- Rezdiffra net sales
- $364.3 million
- Trailing 12 month sales
- $1.3 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.